Vifor Pharma AG

Update on the timeline for Vifor Pharma tender offer

9:21 a.m. May 12, 2022

- BusinessWire - BZX

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

1:00 a.m. April 28, 2022

- BusinessWire - BZX

94th Vifor Pharma Group Annual General Meeting

11:45 a.m. April 26, 2022

- BusinessWire - BZX

DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy

1:00 a.m. April 4, 2022

- BusinessWire - BZX

Publication of definitive end result for Vifor Pharma tender offer

1:00 a.m. March 28, 2022

- BusinessWire - BZX

Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent

2:00 a.m. March 23, 2022

- BusinessWire - BZX

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent

2:00 a.m. March 3, 2022

- BusinessWire - BZX

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

2:00 a.m. Feb. 28, 2022

- BusinessWire - BZX

Vifor Pharma reports sustained growth in 2021

2:00 a.m. Feb. 17, 2022

- BusinessWire - BZX

Vifor Pharma appoints two new members to the Executive Committee

2:00 a.m. Feb. 2, 2022

- BusinessWire - BZX

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.

2:05 a.m. Jan. 18, 2022

- BusinessWire - BZX

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

2:00 a.m. Dec. 21, 2021

- BusinessWire - BZX

Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation

2:00 a.m. Dec. 20, 2021

- BusinessWire - BZX

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma

2:00 a.m. Dec. 16, 2021

- BusinessWire - BZX

CSL Limited announces tender offer to acquire Vifor Pharma Ltd

1:44 a.m. Dec. 14, 2021

- BusinessWire - BZX

Vifor Pharma comments on media speculation

3:59 a.m. Dec. 13, 2021

- BusinessWire - BZX

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

12:45 p.m. Dec. 10, 2021

- BusinessWire - BZX

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee

2:15 a.m. Dec. 10, 2021

- BusinessWire - BZX

Vifor Pharma comments on market speculations

1:40 p.m. Dec. 2, 2021

- BusinessWire - BZX

Vifor Pharma announces changes to the Executive Committee as CFO retires

2:00 a.m. Nov. 30, 2021

- BusinessWire - BZX